Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for LeonaBio, Inc. (LONA).
- 2 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2026, 16:00.
PERCEPTIVE ADVISORS LLC - 26 Oct 2026 Form 4 Insider Report for LeonaBio, Inc. (LONA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- LONA
- Reported as of
- 26 Oct 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2026, 16:00:04 UTC
- Prior SEC filing
- 27 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for LeonaBio, Inc. (LONA) on 26 Oct 2026.
Change
- Previous filing in this sequence was filed on 27 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001224962
Primary reporting owner
PERCEPTIVE ADVISORS LLC
- Relationship
- Director, 10%+ Owner
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
- Signature date
- 26 Oct 2026
CIK 0001164426
EDELMAN JOSEPH
- Relationship
- Director, 10%+ Owner
- Address
- 51 ASTOR PL, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
- Signature date
- 26 Oct 2026
CIK 0001249675
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
- Relationship
- Director, 10%+ Owner
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman
- Signature date
- 26 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LONA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +776,648
- Change %
- Price
- $0.001000*
- Shares after
- 776,648
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F7
LONA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +776,648
- Change %
- Price
- $0.001000*
- Shares after
- 776,648
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F7
LONA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +776,648
- Change %
- Price
- $0.001000*
- Shares after
- 776,648
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,529,566
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,529,566
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,529,566
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 329,756
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F3, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 329,756
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F3, F7
LONA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 329,756
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Footnotes
- F3, F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LONA
transaction
Derivative
Pre-Funded Warrant (right to buy)
Options Exercise
- Transaction value
- Shares
- -776,648
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 776,648
- Exercise price
- $0.001000
- Footnotes
- F1, F4, F5, F6, F7
LONA
transaction
Derivative
Pre-Funded Warrant (right to buy)
Options Exercise
- Transaction value
- Shares
- -776,648
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 776,648
- Exercise price
- $0.001000
- Footnotes
- F1, F4, F5, F6, F7
LONA
transaction
Derivative
Pre-Funded Warrant (right to buy)
Options Exercise
- Transaction value
- Shares
- -776,648
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 776,648
- Exercise price
- $0.001000
- Footnotes
- F1, F4, F5, F6, F7
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 457,645
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 457,645
- Exercise price
- $0.001000
- Footnotes
- F3, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 457,645
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 457,645
- Exercise price
- $0.001000
- Footnotes
- F3, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 457,645
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 457,645
- Exercise price
- $0.001000
- Footnotes
- F3, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to warrant)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,372,935
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,372,935
- Exercise price
- $0.001000
- Footnotes
- F2, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to warrant)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,372,935
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,372,935
- Exercise price
- $0.001000
- Footnotes
- F2, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to warrant)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,372,935
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,372,935
- Exercise price
- $0.001000
- Footnotes
- F2, F6, F7, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,352,932
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,352,932
- Exercise price
- $0.001000
- Footnotes
- F3, F4, F6, F7, F8, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,352,932
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,352,932
- Exercise price
- $0.001000
- Footnotes
- F3, F4, F6, F7, F8, F9
LONA
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,352,932
- Date
- 26 Oct 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,352,932
- Exercise price
- $0.001000
- Footnotes
- F3, F4, F6, F7, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
The securities are directly held by Sermonix Pharmaceuticals, Inc. ("Sermonix"). An affiliate of Perceptive Advisors LLC (the "Advisor") currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix.
Footnote F2
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor.
Footnote F3
The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor.
Footnote F4
The securities were issued to Sermonix in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants became exercisable on March 18, 2026 upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval.
Footnote F5
The Pre-Funded Warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 49.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise.
Footnote F6
The Pre-Funded Warrants do not expire.
Footnote F7
Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Footnote F8
On October 26, 2026, PXV II received from Sermonix Pre-Funded Warrants exercisable for 2,352,932 shares of Common Stock pursuant to a distribution of securities held by Sermonix to holders of Sermonix common stock.
Footnote F9
The Pre-Funded Warrants may not be exercised if, after such exercise, the Master Fund or PVX II, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of its Warrants.